Video

Dr. Rifkin on Corneal Toxicities With Belantamab Mafodotin in Multiple Myeloma

Robert M. Rifkin, MD, FACP, discusses corneal toxicities with belantamab mafodotin-blmf in multiple myeloma.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Robert M. Rifkin, MD, FACP, medical oncologist/hematologist, Rocky Mountain Cancer Centers, discusses corneal toxicities with belantamab mafodotin-blmf (Blenrep) in multiple myeloma.

    In August 2020, the FDA approved belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have received 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

    Regarding safety, belantamab mafodotin is associated with off-target corneal toxicities, says Rifkin. Unlike the corneal toxicities associated with some chemotherapy agents, belantamab mafodotin–associated keratopathy cannot be treated with dexamethasone-containing eyedrops, Rifkin explains.

    The field continues to expand its knowledge of how to best manage ocular toxicities associated with belantamab mafodotin, says Rifkin. Moreover, should a patient develop the adverse effect, it is generally manageable, and its trajectory is predictable. Additionally, not all patients who receive belantamab mafodotin will develop ocular toxicities, concludes Rifkin.

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data